CLEVELAND, Oct. 24, 2019 /PRNewswire/ -- Clinicians
interested in learning more about MRI-guided radiation therapy can
attend a day-long symposium on Friday,
November 14, 2019 in Rome
to understand the strategic, economic, clinical and technical
aspects of starting an MR-image guided radiation therapy program.
The Symposium will feature presentations from various experts in
MRI-guided radiation therapy and an update on the Health Economics
in Radiation Oncology Project (HERO), titled "Access to
Innovative Radiotherapy: How to Make it Happen from an Economic
Perspective," given by co-chair and past president of the
European Society for Radiotherapy and Oncology (ESTRO), Professor
Yolande Lievens.
MRI-guided radiation therapy combines magnetic resonance imaging
(MRI) with radiation delivery to bring soft-tissue visibility to
the treatment of cancer. ViewRay's MRIdian became the world's first
MRI-guided radiation therapy system with patient treatments
commencing in 2014. With five years of clinical usage, MRIdian
represents a new paradigm in radiation oncology allowing clinicians
to visualize, adapt, and target using diagnostic-quality anatomical
detail that's simply unavailable with conventional IGRT
technologies.
The Symposium, titled "Five Years & Counting: Clinical
Experience on MRIdian," will cover current and future applications
for MRI-guided radiation therapy including on-table adaptive
therapy and stereotactic body radiation therapy (SBRT).
Presentations will also cover physics considerations, functional
imaging, ongoing studies and recent clinical findings. The event
will conclude with a tour of the MRIdian MRI-guided Radiation
Therapy System at Gemelli ART.
"We look forward to welcoming clinicians from around the world
to Rome to learn more about the
ground-breaking role of MRI-guided radiation therapy in improving
cancer care," said Professor Vincenzo
Valentini, M.D., Professor of Radiation Oncology and Chair
of the Radiology, Radiation Oncology and Hematology Department at
the Gemelli ART, Fondazione Policlinico Universitario A.Gemelli
IRCCS in Rome. "We're
bringing together some of the field's foremost experts to discuss
all facets of MRI-guided radiation therapy from the economics and
implementation to quality assurance and clinical use. In a single
day, attendees will gather all the information, answers and best
practices they'd need in order to successfully launch an MRI-guided
radiation therapy program."
Presentations featured in the Symposium agenda include:
- Welcome Remarks
Vincenzo Valentini, M.D., Gemelli
ART, Rome, Italy
- MR-Guided RT Primer (The MRIdian Advantage)
Martin Fuss, M.D., Chief Medical
Officer, ViewRay
- Considerations and Challenges of MR-Guided RT
(Physics)
Kristian Boye Ph.D., Rigshospitalet,
Copenhagen, Denmark
- On-Table Adaptive MR Image-Guided RT: Considerations for
QA
Lorenzo Placidi, medical
physicist, Gemelli ART, Rome,
Italy
- MR-Guided Renal Cell Cancer SBRT
Anna Bruynzeel, M.D., Ph.D.,
Amsterdam UMC, Netherlands
- Clinical Studies/Clinical Research
Overview
Paul Strong,
Ph.D., Senior Director, Medical Affairs, ViewRay
- Access to Innovative Radiotherapy: How to Make it Happen
from an Economic Perspective
Yolande Lievens, M.D., Ph.D., Ghent University
Hospital, Ghent, Belgium,
ESTRO-HERO
- On-Table Adaptive MR-Guided SBRT: Clinical Experience at
Gemelli
Luca Boldrini, M.D., Gemelli ART,
Rome, Italy
- Decision Making Process Towards
MRIdian
Pascal
Fenoglietto, M.D., Institut du Cancer Montpellier
(ICM)
- MR-Guided SBRT, Results Phase 2: Prostate SMART study
(Amsterdam UMC Experience)
Frank Lagerwaard, M.D.,
Amsterdam UMC, Netherlands
- Closing Remarks
Piercarlo
Gentile, M.D., San Pietro Fatebenefratelli UPMC,
Rome, Italy
For more information or to register for the symposium please
visit www.VRayExclusive.com. Please note, this event is intended
for medical professionals only, including radiation oncologists,
medical physicists, radiation therapists and hospital
administrators.
About ViewRay
ViewRay, Inc. (Nasdaq: VRAY), designs, manufactures and markets
the MRIdian® radiation therapy system. MRIdian is built upon a
proprietary high-definition MR imaging system designed from the
ground up to address the unique challenges and clinical workflow
for advanced radiation oncology. Unlike MR systems used in
diagnostic radiology, MRIdian's high-definition MR was purpose
built to address specific challenges, including beam distortion,
skin toxicity, and other concerns that potentially may arise when
high magnetic fields interact with radiation beams. ViewRay and
MRIdian are registered trademarks of ViewRay, Inc.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Private Securities Litigation
Reform Act. Statements in this press release that are not purely
historical are forward-looking statements. Such forward-looking
statements include, among other things, the rate of new orders,
upgrades and installations, ViewRay's financial guidance for the
full year 2019 and ViewRay's conference call to discuss its second
quarter results. Actual results could differ from those projected
in any forward-looking statements due to numerous factors. Such
factors include, among others, the ability to commercialize MRIdian
Linac System, demand for ViewRay's products, the ability to convert
backlog into revenue, and the timing of delivery of ViewRay's
products, the timing, results and other uncertainties associated
with clinical trials, the ability to raise the additional funding
needed to continue to pursue ViewRay's business and product
development plans, the inherent uncertainties associated with
developing new products or technologies, competition in the
industry in which ViewRay operates and overall market conditions.
For a further description of the risks and uncertainties that could
cause actual results to differ from those expressed in these
forward-looking statements, as well as risks relating to ViewRay's
business in general, see ViewRay's current and future reports filed
with the Securities and Exchange Commission, including its Annual
Report on Form 10-K for the fiscal year ended December 31, 2018 and its Quarterly Reports on
Form 10-Q for the fiscal quarters ended March 31, 2019 and June
30, 2019, as updated periodically by the company's other
filings with the SEC. These forward-looking statements are made as
of the date of this press release, and ViewRay assumes no
obligation to update the forward-looking statements, or to update
the reasons why actual results could differ from those projected in
the forward-looking statements, except as required by law.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/european-symposium-to-advance-adoption-of-mri-guided-radiation-therapy-300944547.html
SOURCE ViewRay, Inc.